Ambiq CEO exercises options, sells 63,500 shares
Ambiq Micro’s CEO exercised stock options and sold 63,500 shares in September 2026 under a pre-arranged Rule 10b5-1 trading plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ambiq Micro, Inc. (AMBQ) reported that Chief Executive Officer Fumihide Esaka exercised options for a total of 63,500 shares of common stock on September 11 and September 15, 2026, at exercise prices of $8.12 and $12.60 per share and sold 63,500 shares in market transactions. The sales, at weighted average prices generally between the high $50s and mid $60s per share, were made pursuant to a Rule 10b5-1 plan adopted on May 15, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 63,500 shares ($3.24M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
Esaka Fumihide
Role
Chief Executive Officer
Sold
63,500 shs ($3.98M)
Approx. gross sale proceeds
$3.98M
Approx. exercise cost
$740K
Approx. pre-tax spread
$3.24M
Share of Position Sold
12.1%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F3, F8 | 13,500 | $0.00 | $0.00 |
| Exercise | Common Stock F3 | 13,500 | $8.12 | $110K |
| Sale | Common Stock F3, F4 | 3,785 | $59.5626 | $225K |
| Sale | Common Stock F3, F5 | 9,615 | $60.5482 | $582K |
| Sale | Common Stock F3 | 100 | $61.00 | $6K |
| Exercise | Stock Option (Right to Buy) F6 | 19,007 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F7 | 30,993 | $0.00 | $0.00 |
| Exercise | Common Stock | 50,000 | $12.60 | $630K |
| Sale | Common Stock F1 | 42,083 | $63.2661 | $2.66M |
| Sale | Common Stock F2 | 7,917 | $63.8583 | $506K |
Holdings After Transaction:
Stock Option (Right to Buy) — 202,786 contracts (Direct);
Common Stock — 460,460 shares (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 266,286 to 202,786 contracts (Direct);
Common Stock, 460,460 to 460,460 shares (Direct)
Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (8)
- F1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $62.70 to $63.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $63.72 to $64.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The transactions occurred under a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.
- F4. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $58.95 to $59.94 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $59.96 to $60.80 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. 1/48 of the shares subject to the option vested on June 26, 2021, and 1/48 of the shares subject to the option vested in equal monthly installments thereafter, subject to the Reporting Person's continued service.
- F7. 1/4 of the shares subject to the option vested on January 1, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
- F8. 1/4 of the shares subject to the option vested on February 21, 2020, and 1/48 of the shares subject to the option vested in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Key Figures
Total shares exercised: 63,500 shares
Net shares sold: 63,500 shares
Option exercise price: $8.12 per share
+5 more
8 metrics
Total shares exercised
63,500 shares
Options exercised into common stock on September 11 and 15, 2026
Net shares sold
63,500 shares
Total common shares sold across all reported sale transactions
Option exercise price
$8.12 per share
Exercise of 13,500 option shares into common stock
Option exercise price
$12.60 per share
Exercise of 50,000 option shares into common stock
Reported sale price
$59.5626 per share
Sale of 3,785 shares of common stock on September 15, 2026
Reported sale price
$63.2661 per share
Sale of 42,083 shares of common stock on September 11, 2026
Weighted average sale price range
$58.95–$64.05 per share
Price ranges for multiple sale transactions as described in the footnotes
Rule 10b5-1 plan adoption date
May 15, 2026
Date on which the CEO’s trading plan governing these transactions was adopted
Key Terms
Rule 10b5-1 plan, weighted average sale price, vested, equal monthly installments
4 terms
Rule 10b5-1 plan regulatory
"The transactions occurred under a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The reported price in Column 4 is a weighted average sale price."
vested financial
"1/48 of the shares subject to the option vested on June 26, 2021, and 1/48 of the shares subject to the option vested in equal monthly installments thereafter"
equal monthly installments financial
"1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did AMBQ’s CEO report in this Form 4?
The CEO reported exercising options for 63,500 shares of Ambiq Micro common stock on September 11 and 15, 2026, and selling 63,500 shares in market transactions on the same dates, resulting in no net change in shares from these specific exercises.
At what prices did the AMBQ option exercises occur for the CEO?
The reported option exercises for Ambiq Micro’s CEO covered 13,500 shares at an exercise price of $8.12 per share and 50,000 shares at an exercise price of $12.60 per share, converting stock options into an equal number of common shares.
Were the AMBQ CEO’s transactions made under a Rule 10b5-1 plan?
Yes. A footnote states that the reported transactions occurred under a Rule 10b5-1 plan adopted on May 15, 2026, indicating they were executed pursuant to a pre-arranged trading plan rather than being timed discretionarily.
What option grants were exercised by the AMBQ CEO, and when do they expire?
The CEO exercised options covering 13,500 shares with an expiration of February 20, 2029, and options covering 19,007 and 30,993 shares with an exercise price of $12.60, expiring on May 25, 2031 and July 20, 2034, respectively.
AI-generated analysis. How Rhea-AI works. Not financial advice.
